Does medical cannabis treat anxiety or depression?
What the evidence shows
A large international review of randomized trials — the broadest synthesis to date — found no convincing evidence that medical cannabis is effective for common psychiatric conditions such as anxiety, depression or post‑traumatic stress disorder. Researchers systematically pooled data from multiple high-quality clinical trials and concluded that, across the studies evaluated, benefits for these mental health conditions were minimal or absent.
The analysis focused on randomized, controlled trials rather than anecdotal reports or user surveys. That distinction matters because clinical trials are designed to separate true therapeutic effects from placebo responses and other biases. The reviewers emphasized a consistent pattern: trials were often small, short-term, heterogeneous in the types and doses of cannabis products tested, and generally did not demonstrate reliable, clinically meaningful improvements in core psychiatric symptoms.
What clinicians and patients should take away
- Conditions assessed: anxiety disorders, depressive disorders, post‑traumatic stress disorder, and other common psychiatric presentations were among those reviewed.
- Current recommendation: Clinicians should be cautious about recommending cannabis as a treatment for these conditions given the lack of robust trial evidence.
- Risks and uncertainties: Cannabis use carries potential harms — including dependence, cognitive effects, and unpredictable responses depending on product composition — that must be balanced against any hoped-for benefits.
Research gaps
- Larger, longer, and better‑standardized trials are needed that test specific, clinically relevant formulations and dosing schedules.
- Studies should measure both symptom change and functional outcomes, and track adverse effects over longer follow‑up.
Until higher‑quality evidence emerges, established, evidence‑based treatments for anxiety and depression remain the recommended first‑line options.